Combined use of androgen synthesis inhibitors and PARP inhibitors for the treatment of prostate cancer
TW202631149APending Publication Date: 2026-08-01JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- JIANGSU HENGRUI MEDICINE CO LTD
- Filing Date
- 2025-11-04
- Publication Date
- 2026-08-01
Abstract
The present disclosure relates to the combined use of androgen synthesis inhibitors and PARP inhibitors for the treatment of prostate cancer. Specifically, the present disclosure relates to the use of a compound of formula
Need to check novelty before this filing date? Find Prior Art